 This study proposes to examine the combination of CRLX101 in combination with weekly paclitaxel. Preclinical studies show synergistic activity in the SKOV3 human ovarian cancer xenograft ovarian cancer cell lines 14, as well as in vivo 15,16, perhaps via an antiangiogenic mechanism. 